series-c-plus
Stage
1
Investors
About
Egetis Therapeutics is an integrated pharmaceutical company developing late-stage therapies for rare diseases. Its lead product Emcitate (tiratricol) targets MCT8 deficiency (Allan-Herndon-Dudley syndrome) and has received EMA approval, and the company is also developing Aladote (calmangafodipir) for acetaminophen/paracetamol overdose.
Explore Egetis Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.